TauRx’s Data Massage Can't Work Out The Kinks Of Failed LMTX Study
Executive Summary
While the company is hyping the benefit seen in a subgroup analysis of the first Phase III trial of the tau aggregation inhibitor, which failed to show an overall benefit in mild-to-moderate Alzheimer's disease, Datamonitor Healthcare analyst Maha Elsayed raises some questions.
You may also be interested in...
TauRx To File First Tau-Targeting Drug For Alzheimer’s Following Additional Pivotal Data
After previous late-stage setbacks, the Singaporean firm TauRx’s tau aggregation inhibitor asset has succeeded in a pivotal Alzheimer’s disease trial with promising new biomarker data sparking plans for regulatory filings in the US and UK.
Finance Watch: CG Oncology, MBX, Jnana Bring In VC Mega-Rounds
Private Company Edition: In the latest round of $100m-plus venture capital financings, CG Oncology, MBX Biosciences and Jnana Therapeutics raised $120m, $115m and $107m, respectively. Also, MVM Partners closed a $500m fund and former Sage CEO leads incubator ABio-X in Massachusetts.
TauRx Attempts Anti-Tau Comeback But Keeps Data Under Wraps
The firm has revealed its anti-tau candidate showed promise in a late-stage Alzheimer’s study several years after a disappointing failure, but data are yet to be announced in full.